These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22301704)

  • 1. Semi-quantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study.
    Kraus JA; Dabbs DJ; Beriwal S; Bhargava R
    Mod Pathol; 2012 Jun; 25(6):869-76. PubMed ID: 22301704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
    O'Connor SM; Beriwal S; Dabbs DJ; Bhargava R
    Appl Immunohistochem Mol Morphol; 2010 May; 18(3):268-72. PubMed ID: 20186046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.
    Wang HY; Park S; Kim S; Ahn S; Lee D; Kim S; Jung D; Park KH; Lee H
    Int J Clin Exp Pathol; 2014; 7(9):5792-800. PubMed ID: 25337220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
    Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
    Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score.
    Chaudhary LN; Jawa Z; Szabo A; Visotcky A; Chitambar CR
    Hematol Oncol Stem Cell Ther; 2016 Jun; 9(2):48-54. PubMed ID: 26808222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
    Park MM; Ebel JJ; Zhao W; Zynger DL
    Breast J; 2014; 20(1):37-45. PubMed ID: 24261318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.
    Badve SS; Baehner FL; Gray RP; Childs BH; Maddala T; Liu ML; Rowley SC; Shak S; Perez EA; Shulman LJ; Martino S; Davidson NE; Sledge GW; Goldstein LJ; Sparano JA
    J Clin Oncol; 2008 May; 26(15):2473-81. PubMed ID: 18487567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
    Sughayer MA; Alhassoon S; Sughayer HM
    Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT
    Schildgen V; Warm M; Brockmann M; Schildgen O
    Sci Rep; 2019 Dec; 9(1):20266. PubMed ID: 31889145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncotype DX RT-qPCR assay for ER and PR correlation with IHC: a study of 3 different clones.
    Khoury T; Yan L; Liu S; Bshara W
    Appl Immunohistochem Mol Morphol; 2015 Mar; 23(3):178-87. PubMed ID: 24992175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predictive of response to hormone therapy in breast cancer.
    Rastelli F; Crispino S
    Tumori; 2008; 94(3):370-83. PubMed ID: 18705406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies.
    Dixon JM; Cameron DA; Arthur LM; Axelrod DM; Renshaw L; Thomas JS; Turnbull A; Young O; Loman CA; Jakubowski D; Baehner FL; Singh B
    Adv Ther; 2019 Apr; 36(4):828-841. PubMed ID: 30859501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas.
    Acs G; Kiluk J; Loftus L; Laronga C
    Mod Pathol; 2013 Nov; 26(11):1451-60. PubMed ID: 23743933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.